Beenakker Ernesto A C, Maurits Natalia M, Fock Johanna M, Brouwer Oebele F, van der Hoeven Johannes H
Department of Neurology, University Hospital Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands.
Eur J Paediatr Neurol. 2005;9(6):387-93. doi: 10.1016/j.ejpn.2005.06.004. Epub 2005 Aug 15.
Neuromuscular disorders are characterised by progressive muscle weakness, which in time causes functional impairment. To quantify the extent of disease progression, muscle force and functional ability can be measured. Which of these parameters changes most depends on the disease stage. In a previous study, we reported normal values for muscle force obtained by hand-held dynamometry in healthy children aged 4-16 years. In the present study, we report normal values for timed functional tests in healthy children aged 4-11 years. These normal values were compared with values obtained in 16 ambulant patients with Duchenne muscular dystrophy (DMD) aged 5-8 years to study the extent of functional impairment. In ambulant patients with DMD, we found that muscle function assessed by timed functional tests (running 9 m and rising up from the floor) and muscle force assessed by hand-held dynamometry were severely impaired. However, a small reduction of muscle force was accompanied by a large reduction in functional ability. Therefore, in our group of ambulant patients with DMD, timed functional testing was the most sensitive parameter to determine the extent of disease progression. Timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with DMD and possibly in other neuromuscular disorders.
神经肌肉疾病的特征是进行性肌肉无力,随着时间的推移会导致功能障碍。为了量化疾病进展的程度,可以测量肌肉力量和功能能力。这些参数中哪个变化最大取决于疾病阶段。在之前的一项研究中,我们报告了4至16岁健康儿童通过手持测力计获得的肌肉力量正常值。在本研究中,我们报告了4至11岁健康儿童定时功能测试的正常值。将这些正常值与16名5至8岁行走型杜氏肌营养不良症(DMD)患者获得的值进行比较,以研究功能障碍的程度。在行走型DMD患者中,我们发现通过定时功能测试(跑9米和从地面起身)评估的肌肉功能以及通过手持测力计评估肌肉力量严重受损。然而,肌肉力量的小幅下降伴随着功能能力的大幅下降。因此,在我们这组行走型DMD患者中,定时功能测试是确定疾病进展程度最敏感的参数。因此,定时功能测试可被视为药物试验中的一项额外结局指标,以评估治疗对行走型DMD患者以及可能对其他神经肌肉疾病患者的疗效。